



Specialist Medical Review Council

Reasons for Decision

*Section 196W
Veterans' Entitlements Act 1986*

**Re: Statement of Principles No. 72 of 1999
In Respect of Myeloma**
Matter No. 2002/1
Requests for Review Declaration No 7

DECLARATION

1. In relation to the Repatriation Medical Authority (the RMA) Statement of Principles No. 72 of 1999 in respect of myeloma and death from myeloma, made under subsection 196B(2) of the *Veterans' Entitlements Act 1986* (the VEA), the Specialist Medical Review Council (the Council) declares, under subsection 196W(5) of the Act, that it is of the view that the sound medical-scientific evidence available to the RMA at the time it determined, amended, or last amended that Statement of Principles was insufficient to justify:

- (a) an amendment of the Statement of Principles to include as a factor or factors:
 - (i) parasitic diseases, including malaria;
 - (ii) antigenic stimulation; or
 - (iii) parasitic disease, including malaria, precipitating antigenic stimulation; and
- (b) any other amendment of that Statement of Principles.

THE SPECIALIST MEDICAL REVIEW COUNCIL

2. The Council is a body corporate established under section 196V of the VEA, and consists of such number of members as the Minister for Veterans' Affairs determines from time to time to be necessary for the proper exercise of the function of the Council as set out in the VEA. The Minister must appoint one of the Councillors to be the Convener. In the absence of the Convener, the Convener must appoint one of the Councillors selected for the purposes of the review as Presiding Councillor at all meetings of the Council for the purposes of that review.

3. When a review is undertaken of a Statement of Principles made by the RMA, the Council is constituted by 3 to 5 Councillors appointed by the Minister and selected by the Convener. When appointing Councillors, the Minister is required to have regard to the branches of medical science expertise which would be necessary for deciding matters referred to the Council for review.

4. Professor Alex Cohen AO, MD, FRACP was appointed by the Convener as the Presiding Councillor for this review. The other members of the Council were:

- (i) Dr Tony Ryan a Consultant in Public Health and Adjunct Professor and Honorary Senior Fellow of the Department of Public Health at the University of Western Australia;
- (ii) Dr David Joske the Head of the Department of Haematology and Director of Bone Marrow Transplantation at Sir Charles Gairdner Hospital and a Consultant Haematologist from the Western Australia Centre for Pathology and Medical Research "Pathcentre" and Clinical Senior Lecturer of the Department of Medicine at the University of Western Australia; and
- (iii) Dr Noemi Horvath a Senior Haematologist in the Division of Haematology of the Institute of Medical and Veterinary Science of South Australia and Director of the Clinical Haematology and Bone Marrow Transplantation Unit of Royal Adelaide Hospital.

THE LEGISLATION

5. The legislative scheme for the making of Statements of Principles is set out in Parts X1A and X1B of the VEA.

6. The functions and powers of the Council must be seen in light of the function and purpose of Statements of Principles in the scheme of the VEA. The significance of Statements of Principles to claims under the VEA for pensions in

relation to eligible service is apparent from sections 120A and 120B of the VEA. Section 120 is also of importance.

7. Fundamental to Statements of Principles is the concept of ‘sound medical-scientific evidence’ which has been defined in section 5AB(2) of the VEA. Information about a particular kind of injury, disease or death is taken to be sound medical-scientific evidence if:

(a) the information:

- (i) is consistent with material relating to medical science that has been published in a medical or scientific publication and has been, in the opinion of the Repatriation Medical Authority, subjected to a peer review process; or
- (ii) in accordance with generally accepted medical practice, would serve as the basis for the diagnosis and management of a medical condition; and

(b) in the case of information about how that kind of injury, disease or death may be caused – meets the applicable criteria for assessing causation currently applied in the field of epidemiology.

8. The functions of the Council are set out in section 196W of the VEA. In this case, the Council was asked (under section 196Y of the VEA) by a person eligible to make a claim for a pension, to review the contents of Statement of Principles No. 72 of 1999 in respect of myeloma and death from myeloma, being a Statement of Principles determined by the RMA under section 196B(2) of the VEA (‘the reasonable hypothesis standard’).

9. In conducting its review, the Council must review all the information that was available to the RMA at the time it determined, amended, or last amended the Statement of Principles.

10. Under section 196W of the VEA, the Council can only reach the view that a Statement of Principles should be amended on the basis of sound medical-scientific evidence.

BACKGROUND

11. On 28 October 1999, the RMA under subsection 196B(2) of the VEA determined Statement of Principles No. 72 of 1999 in respect of myeloma and death from myeloma.

12. On 10 November 1999 the making of the Statement of Principles was notified in the Gazette (No. 45, p. 3912).

13. On 22 November 1999, in accordance with section 196D of the VEA and sections 46A and 48 of the *Acts Interpretation Act 1901* the Statement of Principles was tabled in both the House of Representatives and in the Senate.

14. On 6 January 2000 the Council received an application for review of Statement of Principles No. 72 of 1999 (the application). Specifically the application was concerned with a decision of the RMA of 28 October 1999 not to add a factor in relation to malaria and other parasitic diseases to Statement of Principles No. 72 of 1999 in respect of myeloma and death from myeloma.

15. The Council held a meeting for the purposes of this review, and heard oral submissions on Friday 12 July 2002.

16. The applicant was unable due to personal circumstances to attend the meeting of the Council held on 12 July 2002, and chose not to have a representative appear before the Council to make an oral submission complementing the applicant's written submission.

17. The Repatriation Commission made a written submission. Dr Jon Kelley, representing the Repatriation Commission, made an oral submission to the Council complementing the written submission at the Council's meeting on 12 July 2002.

SUBMISSIONS

Applicant's submission

18. The application to the Council was supported by two letters from the late Professor W R Pitney who was Dean and Professor of Medicine in the University of New South Wales at the time of their writing. These letters were taken by the Council to comprise the basis upon which the applicant sought review of the Statement of Principles. The letters had previously been submitted by the applicant to the RMA, and were part of 'the information' available to the RMA, the subject of review by the Council.

19. The first of these letters dated 18 August 1983 was addressed to Mr T M Garrett, Pensions Officer for Sydney Legacy. It related to a decision by the Repatriation Commission, on appeal, to reject a relationship between multiple myeloma and other unknown factors, which were accepted for the 'allied conditions' of leukaemia and lymphoma. Professor Pitney expressed the view that,

since myeloma was a condition with a very long latency period, it could well be present for a number of years before the diagnosis was made.

20. The second letter from Professor Pitney dated 17 October 1983 was addressed to Mr F Hibbett, Assistant Pensions Officer Sydney Legacy. In this letter Professor Pitney pointed out once more the long latency period for the development of multiple myeloma making it possible that the genesis of the condition could have its source or 'trigger factor' during war service.

21. In this letter he stated that: 'antigenic stimulation from malaria or other parasitic diseases is associated with proliferation of plasma cells and antibody production.' He postulated that cell proliferation could give rise to the emergence of a mutant cell with neoplastic properties. He posed the question as to how long could such a malignant cell remain dormant, or only proliferate slowly, before the tumour mass reached a size sufficient to cause overt disease.

22. In his letter of 17 October 1983, Professor Pitney drew attention to the long latency period and slow development in numbers of abnormal plasma cells. He stated that there was good evidence for a long period of quiescence before the emergence of disease, or for it not to progress at all to clinically threatening dimensions.

Repatriation Commission's submission

23. The submissions (both written and oral) were made on behalf of the Repatriation Commission by Dr Jon Kelley. In introducing the oral submission Dr Kelley stated that, in the search for relevant material to present to the SMRC, all reports (among the information available to the RMA) that provided epidemiological information on the role of malaria and other parasitic diseases in relation to the development of myeloma had been identified. Additionally, those reports which had explored a relationship between antigenic stimulation and the development of myeloma were also studied in view of the basis of the application for review of the Statement of Principles.

24. In the material which had been so identified there had been a total of 13 reports. All of these provided information on, and consideration of, the relationship (if any) between antigenic stimulation and myeloma. Three reports provided information on the association with malaria, but none contained reference to other parasitic diseases.

25. Dr Kelley stated that the direct evidence on the relationship (if any) between malaria and myeloma comprises three case control studies from Europe and the United States. In the view of the Commission, the best of these was the 1987 study by Koepsell et al, which was a population based study of around 700 myeloma

cases set in the United States. In this study, within those 700 myeloma cases, there were only six that had a history of malaria. No association was found in that study between malaria and myeloma risk.

26. A second study quoted by Dr Kelley was that of Gramenzi et al in 1991, on a smaller group of seven myeloma cases with a history of malaria. A non-statistically significant increase of malaria was found between cases and with an odds ratio adjusted for age and gender of 1.8 and, after further adjustment for some other factors, of 1.6.

27. In both the Koepsell and Gramenzi studies the confidence limits included unity and the results were non-statistically significant.

28. The third study of malaria and myeloma by Cuzick and De Stavola in 1988 was set in hospitals in England and Wales and involved 400 myeloma cases. This study reported finding no association between primary malaria and myeloma risk, but did not provide any numerical data.

29. The Repatriation Commission submitted that the RMA had on two occasions specifically considered whether malaria could play a role in the aetiology of multiple myeloma. The first was in 1997, and was undertaken in response to a letter from Dr John R Sullivan dated 1 May 1996. Dr Sullivan had averred, with references, that malaria was capable of producing immune stimulation citing the Tropical Splenomegaly Syndrome as an instance where hypergammaglobulinaemia occurred in association with peripheral B-cell lymphocytosis or uninhibited B-cell production of IgM and cryoglobulins occurred.

30. The Repatriation Commission submitted, on the basis of the material available to the RMA, and in accordance with the definition of sound medical-scientific evidence in the VEA, that there was:

- (i) no evidence to support the suggestion that parasitic diseases other than malaria; and
- (ii) insufficient evidence to support the suggestion that malaria

are possible links or elements in a reasonable hypothesis connecting operational service with multiple myeloma.

REASONS FOR THE COUNCIL'S DECISION

Pool of information and scope of the review

31. Having reviewed all of the information available to (before) the RMA at the time of creation of the Statement of Principles, the Council was of the view there was no article which was so methodologically flawed that for that or any other reason, it should be excluded from the pool of information. Accordingly, the Council had regard to all the information which was available to the RMA at the time it created the Statement of Principles.

32. After reviewing all the information, the Council decided to confine its attention to the factor/s contended for by the applicant. The Council's task was thus to ascertain whether there was sufficient sound medical-scientific evidence that:

- (i) parasitic diseases, including malaria;
- (ii) antigenic stimulation; or
- (iii) parasitic disease, including malaria, precipitating antigenic stimulation;

(if found to exist in a particular case) could provide a link or element in a reasonable hypothesis connecting operational service to myeloma and death from myeloma.

The Council's analysis of 'the Information'

Consideration of the Applicant's Submission

33. The primary focus of the applicant's submission was that antigenic stimulation constituted a possible link or element connecting operational service with myeloma and death from myeloma. Consideration of whether antigenic stimulation might be responsible in some way for triggering changes that ultimately result in the development of myeloma, has engaged scientific attention for some time. The Council noted that most of the studies seeking to establish this link took place about twenty years ago, as reflected in the views of Professor Pitney, which formed the basis of the applicant's submission. The Council found that since 1994 there have been very few articles supporting this contention.

34. However, as recently as 1995 the authoritative text, the *Oxford Textbook of Oncology*, stated at page 1853:

It is attractive to speculate that myeloma may, in some part, be either initiated or promoted by chronic antigenic stimulation. High levels of polyclonal immunoglobulins in black populations and anecdotal cases of specificity of the paraprotein for a known antigen provide some support for this view but it remains unproven.

35. It was evident from the information available to the RMA that the esteemed Australian scientist, Professor Don Metcalf, had been approached on a number of occasions for his opinion (in some based upon specific instances) as to the connection (if any) between past exposure to malaria and the subsequent development of lymphosarcoma. In a letter dated 12 April 1983 he commented:

Although this case was argued on the basis of malarial infections, an equal argument could have been made on the basis of any number of severe and/or sustained infections suffered during war service. [After listing a number of possible examples Professor Metcalf continued]: A sensible set of guidelines here would be: Was the infection **systemic**? Was it '**severe**' eg malaria, dengue? Were there **repeated** episodes of infection? (emphasis added)

Although the case happened to be argued on four cases of lymphosarcoma, it could equally have been argued on the basis of other cancers of lymphoid tissues or some types of leukaemia. These are all cancers of the sets of white cells whose proliferation is stimulated by foreign antigens.

36. Professor Metcalf then went on to list a number of β -lymphocyte cancers, including multiple myeloma that he considered would come under this rubric. He then itemised a number of cancers for which there was no evidence of a connection between infections and subsequent cancer development, and concluded with three specific infections – hepatitis B virus, schistosomiasis and human T-cell virus infection – in respect of each of which he considered there was indisputable evidence for a causal relationship.

37. In a letter dated 1 November 1989 Professor Metcalf drew attention to his previous opinions in 1983 and 1986 in which he had considered:

the possibility that severe, recurrent or generalised infection such as malaria might be a contributing factor to the subsequent development in a later life of a cancer of β -lymphocytes such as multiple myeloma. The proposed link was at best tenuous.

38. Further, Professor Metcalf in his letter of 1 November 1989 drew attention to numerous experiments which his group had carried out over the years to substantiate the possibility that severe and sustained antigenic stimulation might produce malignant change in blood cells. He stated that:

in no instance has leukaemia or cancer of blood cells resulted. **Our published conclusions from these studies are that, when normal blood cells are placed under intense proliferative stimulation, this situation does not result in the subsequent development of cancer in these cells. In the light of these subsequent studies I am now of the opinion that the original hypothesis proposing such a link is untenable** (emphasis added).

39. The final paragraph of Professor Metcalf's letter of 1 November 1989 states:

I am therefore of the opinion that **there is no reasonable hypothesis linking the malaria likely to have been suffered by this veteran during his war service and the subsequent development by him of multiple myeloma** (emphasis added).

40. In a letter dated 18 February 1991, Professor Metcalf reiterated these views. Whilst not dealing specifically with multiple myeloma, he stated his own experience, and that of his group, as being unable to substantiate a role for chronic infection/antigenic stimulation in the development of haemopoietic disorders.

Consideration of the Repatriation Commission's written and oral submissions

41. The Council noted the paucity of studies that point to a link between malaria and myeloma.

42. The Council applied standard epidemiological criteria to the studies referred to in the Repatriation Commission's submissions. The Council agreed the few investigations which had been undertaken did not support a link, particularly in terms of strength of association, biological gradient and consistency.

43. There was considerable discussion concerning the relationship between the B-cell and immune suppression of T lymphocytes. The consensus of the Council was that this stimulation followed a different pathway from that associated with the proliferation of B-cells in myeloma, and that no true correlation in epidemiological terms could be established.

Council's Conclusions

Malaria

44. The Council accepted that malaria interacts with the immune system in a pronounced way, such as in the Tropical Splenomegaly Syndrome. However, it was of the view that this was an isolated response. The great majority of those persons suffering from malaria do not show this particular response. This response does not occur sufficiently often to satisfy epidemiological criteria of a link with myeloma. Further, although myeloma is known to be a chronic B-cell malignancy and there is known to be an increased incidence of B-cell malignancies in

conditions of T-cell immunosuppression, such immunosuppression is not known to be present as a consequence of malaria.

45. On the basis of these considerations, the Council was of the view that there was insufficient sound medical-scientific evidence that malaria could provide a link or element in a reasonable hypothesis connecting operational service to myeloma and death from myeloma.

Antigenic Stimulation

46. The Council considered that if there were a connection between antigenic stimulation and myeloma (either alone or in combination with malaria or other parasitic diseases) it would be expected that studies would have identified a much larger number of cases pointing to such a link. On the contrary, the Council noted only sparse and tenuous linkage had been identified.

47. The Council noted further that attempts had been made to link the idio-type of the antibody of the paraprotein to common antigens. As a result, it had been shown that a lot of paraproteins are directed towards a variety of particular external stimuli. This tended rather more to favour as a link to myeloma familial association, rather than antigenic association.

48. Although the suggested link had seemed interesting and attractive during that period in which Professor Pitney's letters had been written and Professor Metcalf had first considered the hypothesis further research and opinion had subsequently failed to support such a link.

49. The Council noted Professor Metcalf's conclusion that the hypothesis (to which he had originally subscribed) that placing normal blood cells under intense proliferative stimulation resulted in the subsequent development of cancer in those cells, was untenable. The Council considered Professor Metcalf's conclusion (that the appropriate epidemiological and clinical criteria were lacking) was supported by the studies of Koepsell et al (SMRC Folder 4, Article 36); Eriksson (SMRC Folder 3, Article 26); Lewis et al (SMRC Folder 3, Article 14); Linet et al (SMRC Folder 4, Article 37).

50. Whilst the requisite connectivity might have been considered a reasonable hypothesis at the time of its first formulation (in or about 1983) there was now a significant body of sound medical-scientific evidence which refuted and discredited it.

51. On the basis of these considerations, the Council was of the view that there was insufficient sound medical-scientific evidence that antigenic stimulation could provide a link or element in a reasonable hypothesis connecting operational

service to myeloma and death from myeloma. While this might have been considered a reasonable hypothesis at the time of its first formulation, the Council concluded there was now a significant body of sound medical-scientific evidence to refute it.

Parasitic disease, including malaria, precipitating antigenic stimulation

52. For the reasons set out above, the Council concluded that there was insufficient sound medical-scientific evidence that antigenic stimulation (however caused) could provide a link or element in a reasonable hypothesis connecting operational service to myeloma and death from myeloma. Consequently, the Council necessarily concluded that there was similarly insufficient sound medical-scientific evidence that antigenic stimulation, precipitated by parasitic disease, including malaria, could provide a link or element in a reasonable hypothesis connecting operational service to myeloma and death from myeloma.

DECISION

53. For the reasons discussed above, the Council was unanimous in its decision that the sound medical-scientific evidence available to the RMA at the time it determined, amended, or last amended Statement of Principles No. 72 of 1999 was insufficient to support:

- (i) parasitic diseases, including malaria;
- (ii) antigenic stimulation; or
- (iii) parasitic disease, including malaria, precipitating antigenic stimulation;

as a link or element in a reasonable hypothesis connecting operational service to myeloma and death from myeloma. Further the Council was of the view that the sound medical-scientific evidence available to the RMA at the relevant times was insufficient to justify any other amendment of Statement of Principles No. 72 of 1999. Accordingly, the Council made the Declaration set out in paragraph 1 above.

EVIDENCE BEFORE THE COUNCIL

Documents

54. The information considered by the Council (being the information which was available to the RMA and sent to the Council by the RMA in accordance with section 196K of the VEA) was as is listed in Appendix A.

Appendix A

SMRC Folder No.	Title No	Title
3	1	Koranda FC (1981). Antimalarials. J Am. Acad. Dermatol 4(6) pp 650-655.
3	2	Hoar Zahm S, Blair A and Weisenburger DD (1992). Sex differences in the risk of multiple myeloma associated with agriculture. British Journal of Industrial Med. Vol 49 pp 815-816.
3	3	Demers PA, Boffetta P, et.al (1995). Pooled reanalysis of cancer mortality among five cohorts of workers in wood-related industries. Scand J. Work Environ Health Vol 21 pp 179-190.
3	4	Aksoy M (1989). Hematotoxicity and carcinogenicity of benzene (1989). Environmental Health Perspectives Vol 82 pp 193-197.
3	5	Wong O, Trent LS and Whorton MD (1994). An updated cohort mortality study of workers exposed to styrene in the reinforced plastics and composites industry. Occup. Environ. Med. Vol 51 pp 386-396.
3	6	Wong O (1995). Risk of acute myeloid leukaemia and multiple myeloma in workers exposed to benzene. Occup. Environ.Med. Vol 52 pp 380-384.
3	7	Ichimaru M and Mabuchi K (1991). Multiple myeloma among atomic bomb survivors - II. Biological effects. J. Radiat. Res. Supp. pp 168-171.
3	8	Morris Brown L, Burmeister LF, Everett and Blair A (1993). Pesticide exposures and multiple myeloma in Iowa men. Cancer Causes and Control Vol 4 pp 153-156.
3	9	Morris Brown L, Gibson R, Burmeister LF Schuman LM, Everett GD and Blair A (1992). Alcohol consumption and risk of leukemia, non-hodgkin's lymphoma, and multiple myeloma. Leukemia Research 16(10) pp 979-984.
3	10	Friedman GD and Herrinton LJ (1994). Obesity and multiple myeloma. Cancer Causes and Control Vol 5 pp 479-483.

- 3 11 Heineman EF, Hoar Zahm S, McLaughlin JK, Vaught JB and Hrubec Z (1992). A prospective study of tobacco use and multiple myeloma: evidence against an association. *Cancer Causes and Control* Vol 3 pp 31-36.
- 3 12 Heineman EF, Olsen JH, Pottern LM, Gomez M, Raffin E and Blair A (1992). Occupational risk factors for multiple myeloma among Danish men. *Cancer Causes and Control* Vol 3 pp 555-568.
- 3 13 Herrinton LJ, Koepsell TD and Weiss NS (1992). Comment - Smoking and multiple myeloma. *Cancer Causes and Control* Vol 3 pp 391-392.
- 3 14 Lewis DR, Pottern LM, Brown LM et.al (1994). Multiple myeloma among blacks and whites in United States: the role of chronic antigenic stimulation. *Cancer Causes and Control* Vol 5 pp 529-539.
- 3 15 Pottern LM, Heineman EF, Olsen JH, Raffin E and Blair A (1992). Multiple myeloma among Danish women: employment history and workplace exposures. *Cancer Causes and Control* Vol 3 pp 427-432.
- 3 16 Filipovich AH, Spector BD and Kersey J (1980). Immunodeficiency in humans as a risk factor in the development of malignancy. *Preventive Medicine* Vol 9 pp 252-259.
- 3 17 Friedman GD (1986). Multiple myeloma: Relation to propoxyphene and other drugs, radiation and occupation. *International Journal of Epidemiology* 15(3) pp 424-426.
- 3 18 Selected Cancers Cooperative Study Group (1990). The Association of selected cancers with service in the US military in Vietnam. 1. Non-Hodgkin's Lymphoma. *Arch Intern Med.* Vol 150 pp 2473-2483.
- 3 19 Cuzick J (1981). Special Article - Radiation-Induced Myelomatosis. *N Engl. J Med.* 304(4) pp 204-210.
- 3 20 Lloyd RD and Taylor GN (1991). NTS Fallout-induced multiple myeloma in Utah-(Correspondence). *Health Physics* 61(5) pp 671-674.

- 3 21 Uchiumi H, Murakami H, Matsushima T, Tamura J, Sawamura M, Naruse T and Tsuchiya J (19??). Does sarcoidosis induce multiple myeloma? Letters and Correspondence page 220.
- 3 22 Morrison HI, Wilkins K, Semenciw R, Mao Y and Wigle D (1992). Review - Herbicides and Cancer. Journal of the Natl. Cancer Inst. 84(24) pp 1866-1874.
- 3 23 McIntyre OR (19??). Myeloma - Chapter 28 - Part Two Specific Neoplasms pp 433-435, 452-457.
- 3 24 Herrinton LJ, Weiss NS, Koepsell TD et.al (1994). Exposure to hair-coloring products and the risk of multiple myeloma. Am.Journal of Public Health 84(7) pp 1142-1144.
- 3 25 Joseph G, Barker RL, Yuan B, Martin A, Medeiros J and Peiper SC (1994). Posttransplantation plasma cell dyscrasias. Cancer 74(7) pp 1959-1964.
- 3 26 Eriksson M (1993). Rheumatoid arthritis as a risk factor for multiple myeloma: A case-control study. Eur. J Cancer 29A(2) pp 259-263.
- 3 27 Brownson RC (1991). Cigarette smoking and risk of multiple myeloma. Journal of the Natl. Cancer Inst. 83(14) pp 1036-1037.
- 3 28 Morris Brown L, Everett GD, Burmeister LF and Blair A (1992). Hair dye use and multiple myeloma in white men. Am. J. Public Health 82(12) pp 1673-1674.
- 3 29 Boice Jr. JD, Morin MM, Glass AG et.. al (1991). Diagnostic X-ray procedures and risk of leukemia, lymphoma and multiple myeloma. JAMA 265(10) pp 1290-1294.
- 3 30 Hansen ES (1993). A follow-up study on the mortality of truck drivers. Am. Journal of Industrial Medicine Vol 23 pp 811-821.
- 3 31 Eriksson M and Karlsson M (1992). Occupational and other environmental factors and multiple myeloma: A population based case-control study. British Journal of Industrial Medicine Vol 49 pp 95-103.
- 3 32 Demers PA, Vaughan TH et.al (1993). A case-control study of multiple myeloma and occupation. American Journal of Industrial Medicine Vol 23 pp 629-639.

- 3 33 Council on Scientific Affairs (1988). Cancer risk of pesticides in agricultural workers - Council Report. *JAMA* 260(7) pp 959-966.
- 3 34 Bourguet CC and Logue EE (1993). Antigenic stimulation and multiple myeloma. *Cancer* 72(7) pp 2148-2154.
- 3 35 Lindquist R, Nilsson B, Ellund G and Gahrton G (1987). Increased risk of developing acute leukemia after employment as a painter. *Cancer* Vol 60 pp 1378-1384.
- 3 36 Morris P D, Koepsell T D, Daling J R, Taylor J W, Lyon J L, Swanson G M, Child M and Weiss N S (1986) Toxic substance exposure and multiple myeloma: A case-control study. *JNCI* Vol 76 No 6 pp 987-994.
- 3 37 Schnatter AR, Katz AM, Nicolich MJ & Theriault G (1993) A Retrospective Mortality Study among Canadian Petroleum Marketing and Distribution Workers *Environmental Health Perspectives Supplements* 101 (Suppl 6) pp 85 - 99.
- 3 38 Christie D, Robinson K, Gordon I and Bisby J (1991). A prospective study in the Australian petroleum industry. II. Incidence of cancer. *British Journal of Industrial Med.* Vol 48 pp 511-514.
- 3 39 Inskip PD, Kleinerman RA, Stovall M, Cookfair DL et. al (1993). Leukemia, lymphoma and multiple myeloma after pelvic radiotherapy for benign disease. *Radiation Research* Vol 135 pp 108-124.
- 3 40 Ott MG, Teta MJ and Greenberg HL (1989). Lymphatic and hematopoietic tissue cancer in a chemical manufacturing environment. *Am. Journal of Industrial Med.* Vol 16 pp 631-643.
- 3 41 Bertazzi PA, Pesatori AC, Consonni D, et al (1993). Cancer incidence in a population accidentally exposed to 2,3,7,8-Tetrachlorodibenzo-para-dioxin. *Epidemiology* 4(5) pp 398-406.
- 3 42 Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E et. al. (1994). Cancer incidence in atomic bomb survivors. Part III: Leukemia, lymphoma and multiple myeloma, 1950-1987, *Radiation Research* Vol 137 pp S68-S97.

- 3 43 Bethwaite PB, Pearce N and Fraser J (1990) Cancer risk in painters: study based on the New Zealand Cancer Registry. *British J of Industrial Medicine* Vol 47 pp 742-6.
- 3 44 Hoar Zahm S, Weisenburger DD, Babbitt PA, Saal RC, Vaught JB and Blair A (1992). Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. *Am J Pub Health* 82(7) pp 990-998.
- 3 45 Linet MS, McLaughlin JK, Malker HSR, Chow W, Weiner JA, Stone BJ, Ericsson JLE and Fraumeni JF (1994). Occupation and hematopoietic and lymphoproliferative malignancies among women: a linked registry study. *JOM* 36(11) pp 1187-1198.
- 3 46 Viel JF and Richardson ST (1993). Lymphoma, multiple myeloma and leukaemia among French farmers in relation to pesticide exposure. *Soc Sci Med.* 37(6) pp 771-777.
- 3 47 Blair A, Hoar Zahm S, Pearce N E, Heineman EF and Fraumeni JF (1992). Clues to cancer etiology from studies of farmers. *Scand J Work Environ Health*, 1992, Vol 18 pp 209-215.
- 4 1 Pukkala E and Notkola V (1997). Cancer incidence among Finnish farmers, 1979-93. *Cancer Causes and Control*, Vol 8 pp 25-33.
- 4 2 Anttila A, Pukkala E, Sallmen M, Hernberg S and Hemminki K (1995). Cancer incidence among Finnish workers exposed to halogenated hydrocarbons. *JOEM*, 37(7) pp 797-806.
- 4 3 Bertazzi PA, Zocchetti C, Guercilena S, Consonni D, Tironi A, Landi MT & Pesatori AC. (1997). Dioxin exposure and cancer risk: a 15-year mortality study after the "Seveso Accident". *Epidemiology*, Vol 8 (6) pp 646-52.
- 4 4 Sans S, Elliott P, Kleinschmidt I, Shaddick G, Pattenden S, Walls P, Grundy C and Dolk H (1995). Cancer incidence and mortality near the Baglan Bay petrochemical works, South Wales. *Occupational and Environmental Medicine*, Vol 53 pp 217-224.
- 4 5 La Vecchia C, Negri E, D'Avanzo B and Franceschi S (1989). Occupation and lymphoid neoplasms. *British Journal of Cancer*, Vol 60 pp 385-388.

- 4 6 Christie D, Robinson K, Gordon I and Bisby J (1991). A prospective study in the Australian petroleum industry. II Incidence of cancer. *British Journal of Industrial Medicine*, Vol 48 pp 511-514.
- 4 7 Christie D, Robinson K, Gordon I and Bisby J (1991). A prospective study in the Australian petroleum industry. I Mortality. *British Journal of Industrial Medicine*, Vol 48 pp 507-510.
- 4 8 Yardley-Jones A, Anderson D and Parke DV (1991). The toxicity of benzene and its metabolism and molecular pathology in human risk assessment. *British Journal of Industrial Medicine*, Vol 48 pp 437-444.
- 4 9 Khuder SA & Mutgi AB. (1997). Meta-analyses of multiple myeloma and farming. *American Journal of Industrial Medicine*, Vol 32 (5) pp 510-6.
- 4 10 Bezabeh S, Engel A, Morris CB & Lamm SH. (1996). Does benzene cause multiple myeloma? An analysis of the published case-control literature. *Environmental Health Perspectives*, Vol 104 Suppl 6 pp 1393-8.
- 4 11 Wong O & Raabe GK. (1997). Multiple myeloma and benzene exposure in a multinational cohort of more than 250,000 petroleum workers. *Regulatory, Toxicology & Pharmacology*, Vol 26 pp 188-199.
- 4 12 Fritschi L & Siemiatycki J. (1996). Lymphoma, myeloma and occupation: results of a case-control study. *International Journal of Cancer*, Vol 67 (4) pp 498-503.
- 4 13 Savitz DA, Andrews KW. (1996). Risk of myelogenous leukemia and multiple myeloma in workers exposed to benzene. *Occupational & Environmental Medicine*, Vol 53 (5) pp 357-8.
- 4 14 Durie BGM (1996). Multiple myeloma. A concise review of the disease and treatment options. *International Myeloma Foundation*, Los Angeles.
- 4 15 Sheil AGR. (1995). Malignancy following liver transplantation: a report from the Australian combined liver transplant registry. *Transplantation Proceedings*, Vol 27 (1) p 1247.

- 4 16 Wing S, Richardson D, Armstrong D and Crawford-Brown D (1997). A Reevaluation of Cancer Incidence near the Three Mile Island Nuclear Plant: The Collision of Evidence and Assumptions. *Environmental Health Perspectives* 105 (1) pp 52-57
- 4 17 Hatch M, Susser M and Beyea J (1997). Comments on "A Reevaluation of Cancer Incidence near the Three Mile Island Nuclear Plant". *Environmental Health Perspectives* 105 (1) pp 12
- 4 18 Anonymous (1997), Revisiting Three Mile Island. *Environmental Health Perspectives* 105 (1) pp 22-23
- 4 19 Little MP & Muirhead CR (1996). Evidence for curvilinearity in the cancer incidence dose - response in the Japanese atomic bomb survivors. *International Journal of Radiation Biology* 70 (1) pp 83-94
- 4 20 Bland JM. (1994). Cancer in nuclear test veterans. Statistical analysis inappropriate. *British Medical Journal*. Vol 308 (6924) pp 339-40.
- 4 21 Rahu M, Tekkel M, Veidebaum T, Pukkala E, Hakulinen T, Auvinen A, Rytomaa T, Inskip PD & Boice Jd Jr. (1997). The Estonian study of Chernobyl cleanup workers: II. Incidence of cancer and mortality. *Radiation Research*, Vol 147, pp653-657.
- 4 22 Fry Rj. (1996). Effects of low doses of radiation. *Health Physics*. Vol 70 (6) pp 823-7.
- 4 23 Zulian GB. (1997). Multiple Myeloma: Clinical evaluation of plasma cell lymphoproliferative disorders and initial management. *Seminars in Haematology*, Vol. 34 (S1), pp. 29-39.
- 4 24 Preston-Martin S, Pike MC, Ross RK, Jones PA and Henderson BE (1990). Increased cell division as a cause of human cancer. *Cancer Research*, Vol 50 pp 7415-7421.
- 4 25 Flodin, U., Fredriksson, M., & Persson, B. (1987). Multiple myeloma and engine exhausts, fresh wood, and creosote: A case-referent study. *American Journal of Industrial Medicine*, Vol. 12, pp. 519-529.

- 4 26 Darby, S.C., Kendall, G.M., Fell, T.P., O'Hagan, J.A., Muirhead, C.R., Ennis, J.R., Ball, A.M., Dennis, J.A., & Doll, R. (1988). A summary of mortality and incidence of cancer in men from the United Kingdom who participated in the United Kingdom's atmospheric nuclear weapon tests and experimental programmes. *British Medical Journal* Vol 296, 30 January, pp.332-338.
- 4 27 Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelmann JH and Friedman GD (1994). *Helicobacter pylori* infection and gastric lymphoma. *N Engl J Med* 330(18) pp 1267-1271.
- 4 28 Isaacson PG (Editorial)(1994). Gastric lymphoma and *helicobacter pylori*. *N Engl J Med* 330(18) pp 1310-1311.
- 4 29 GANN Monograph on Cancer Research No. 32 (1986) (pp 1-28). *Cancer in Atomic Bomb Survivors*. Japan Scientific Societies Press, Tokyo, (1) Itsuzo Shigematsu & Suminori Akiba pp 1-8; (2) Takashi Maruyama pp 9-28.
- 4 30 Faustini A, Forastiere F, Di Betta L, Magliola EM and Perucci CA (1993). Cohort study of mortality among farmers and agricultural workers. *Med. Lav* Vol 84 pp 31-41.
- 4 31 Friedman GD (1993). Cigarette smoking, leukemia and multiple myeloma. *Ann. Epidemiol.* 3(4) 00 425-428.
- 4 32 Boffetta P, Stellman SD and Garfinkel L (1989). A case-control study of multiple myeloma nested in the American cancer society prospective study. *Int. J. Cancer* Vol 43 pp 554-559.
- 4 33 Cohen HJ, Bernstein RJ and Grufferman S (1987). Role of immune stimulation in the etiology of multiple myeloma: A case-control study. *American Journal of Hematology* Vol 24 pp 119-126.
- 4 34 Doody MM, Linet MS, Glass AG et.al (1992). Leukemia, lymphoma and multiple myeloma following selected medical conditions. *Cancer Causes and Control* Vol 3 pp 449-456.
- 4 35 Gramenzi A, Buttino I, D'Avanzo B, Negri E, Franceschi S and LaVecchia C (1991). Medical history and the risk of multiple myeloma. *Br. J. Cancer* Vol 63 pp 769-772.

- 4 36 Koepsell TD, Daling JR, Weiss NS et. al (1987). Antigenic stimulation and the occurrence of multiple myeloma. *American Journal of Epidemiology* 126(6) pp 1051-1062.
- 4 37 Linet MS, Harlow SD and McLaughlin JK (1987). A case-control study of multiple myeloma in whites: Chronic Antigenic stimulation, occupation and drug use. *Cancer Research* Vol 27 pp 2978-2981.
- 4 38 Kyle RA (1994). Monoclonal gammopathy of undetermined significance. *Blood Reviews* 8(3) pp 135-141.
- 4 39 Paxton MB, Chinchilli VM, Brett SM and Rodricks JV (1994). Leukemia risk associated with benzene exposure in the pliofilm cohort: 1. Mortality update and exposure distribution. *Risk Analysis* 14(2) pp 147-154.
- 4 40 Barlogie B and Gale RB (1992). Multiple myeloma and chronic lymphocytic leukemia: Parallels and contrasts. *The American Journal of Med.* Vol 93 pp 443-450.
- 4 41 Chucrallah AE, Crow MK, Rice LE, Rajagopalan S and Hudnall SD (1994). Multiple myeloma after cardiac transplantation: An unusual form of posttransplant lymphoproliferative disorder. *Human Pathology* 25(5) pp 541-545.
- 4 42 Cuzick J (1994). Multiple Myeloma. *Cancer Surveys* Vol 19: Trends in Cancer Incidence and Mortality pp 455-474.
- 4 43 Kumar S, Kumar D, Schnadig VJ et. al (1994). Hematopathology - Plasma cell myeloma in patients who are HIV-positive. *Am. J Clin. Pathol* 102(5) pp 633-639.
- 4 44 Ong F, Hermans J, Noordijk EM and Kluin-Nelemans JC (1995). Is the Durie and Salmon diagnostic classification system for plasma cells dyscrasias still the best choice? *Ann Hematol* Vol 70 pp 19-24.
- 4 45 Rinsky RA, Smith AB, Hornung R et.al (1987). Benzene and Leukemia. An epidemiologic risk assessment. *N Engl.J of Med.* 316 (17) pp 1044-1050.

- 4 46 Wong O, Harris F and Smith TJ (1993). Health effects of gasoline exposure. II. Mortality patterns of distribution workers in the United States. *Environmental Health Perspectives Supplements* 101 (Suppl. 6) pp 63-76.
- 4 47 Semenciw RM, Morrison HI, Riedel D, Wilkins K, Ritter L and Mao Y (1993). Multiple myeloma mortality and agricultural practices in the Prairie Provinces of Canada. *JOM* 35(6) pp 557-561.
- 5 1 Szekely L, & Klein G. (1997). Multiple myeloma and Kaposi's sarcoma-associated herpesvirus-a paracrine model of tumorigenesis? *Trends in Microbiology*, Vol 5 (11) pp 424-5. Discussion pp 425-6.
- 5 2 Weimer K, Talbott EO, Day RD. (1998). Further examination of employment in the chemical industry: follow-up case-control study of hematopoietic and lymphoid neoplasms using a next consecutive death control group. *American Journal of Industrial Medicine*, Vol 33, pp97-98.
- 5 3 Ozkalemkas F, Ali R, Tunali A, Ozkocaman V, Ozyardimsi C, & Ozcelik T. (1996). Multiple myeloma in the region of Bursa, Turkey: a retrospective analysis. *Journal of Environmental Pathology, Toxicology & Oncology*, Vol 15 (2-4) pp 267-70.
- 5 4 Howe GR & Burch JD. (1990). Fire fighters and risk of cancer: an assessment and overview of the epidemiologic evidence. *American Journal of Epidemiology*, Vol 132 (6) pp 1039-1050.
- 5 5 Shiel AGR, Flavel S, Disney APS, & Mathew TH. (1985). Cancer in dialysis and transplant patients. *Transplantation Proceedings*, Vol 17 pp 195-8.
- 5 6 Brown LM, Pottern LM, Silverman DT, Schoenberg JB, Schwartz AG, Greenberg RS, Hayes RB, Liff JM, Swanson GM, & Hoover R. (1997). Multiple myeloma among Blacks and Whites in the United States: role of cigarettes and alcoholic beverages. *Cancer Causes & Control*, Vol 8, pp610-614.
- 5 7 Nanni O, Falcini F, Buitti E, Bucchi L, Naldoni M, Serra P, Scarpi E, Saragoni L, & Amadori D. (1998). Multiple myeloma and work in agriculture: results of a case-control study in Forli, Italy. *Cancer Causes & Control*, Vol 9 (3) pp 277-83.

- 5 8 Alberts SR & Lanier AP. (1997). Correspondence re: GG Schwartz, Multiple myeloma: clusters, clues, and dioxins. *Cancer Epidemiol. Biomark. Prev.*, 6: 49-56, 1997. *Cancer Epidemiology, Biomarkers & Prevention*, Vol 6 pp 857-858.
- 5 9 Schwartz GG. (1997). Multiple myeloma: clusters, clues, and dioxins. *Cancer Epidemiology, Biomarkers & Prevention*, Vol 6 pp 49-56.
- 5 10 Koessel SL, Theis MK, Vaughan TL, Koepsell TD, Weiss NS, Greenberg RS, & Swanson GM. (1996). Socioeconomic status and the incidence of multiple myeloma. *Epidemiology*, Vol 7 (1) pp 4-8.
- 5 11 Delzell E (1996). Beyond social class. *Epidemiology*, Vol 7(1) pp 1-3.
- 5 12 Roff SR. (1999). Atomic Tests. A long time coming. After forty years, the human fallout from British nuclear tests is increasing. *New Scientist*, p51.
- 5 13 Jyothirmayi R, Gangadharan VP, & Rajan B. (1997). Radiotherapy in the treatment of solitary plasmacytoma. *The British Journal of Radiology*, Vol 70 pp 511-6.
- 5 14 Grardel B, Fauquert P, Hardouin P. (1997). Malignancy in patients with rheumatoid arthritis treated with methotrexate. *The Journal of Rheumatology*, Vol 24 (4) pp 805-6.
- 5 15 Usman AR & Yunus MB. (1996). Non-Hodgkin's Lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate. *J Rheumatology*, Vol 23 pp 1095-7.
- 5 16 Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, & Alexanian R. (1998). Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. *Int J Radiation Oncology Biol Phys*, Vol 41(5) pp 1063-7.
- 5 17 Nilsson RI, Nordlinder R, Horte LG and Jarvholm B (1998). Leukaemia, lymphoma, and multiple myeloma in seaman on tankers. *Occupational and Environmental Medicine*, Vol 55 pp 517-521

- 5 18 Jaccard A, Touati M, Sol C, Bordessoule D, Couty JP, Rogez S, Trimoreau F, Dupuytren CHRU. (1998). Human herpesvirus-8 and relatives of patients with plasmocytic diseases. *Blood* Vol 92(9) p3488.
- 5 19 Schonrich G, Raftery M, Schnitzler P, Rohr U, Goldschmidt H. (1998). Absence of a correlation between Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) and multiple myeloma. *Blood* Vol 92 (9) pp 3474-5.
- 5 20 Fiorino AS & Atac B. (1997). Paraproteinemia, plasmacytoma, myeloma and HIV infection. *Leukemia*, Vol 11 pp2150-6.
- 5 21 Rajkumar SV, Gertz MA, Kyle RA. (1998). Primary systemic amyloidosis with delayed progression to mutiple myeloma. *Cancer* Vol 82 pp1501-5.
- 5 22 Hallek M, Bergsagel PL, & Anderson KC. (1998). Mutiple myeloma: increasing evidence for a multistep transformation process. *Blood*, Vol 91(1) pp 3-21.
- 5 23 Hjalgrim H, Frisch M & Melbye M. (1998). Incidence rates of classical Kaposi's sarcoma and mutiple myeloma do not correlate. *British Journal of Cancer*, Vol 78(3) pp419-420.
- 5 24 Rettig MB, Said JW, Sun R, Vescio RA, Berenson JR. (1997) Discussion; Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from mutiple myeloma patients. *Science* Vol 278 pp1972-3.
- 5 25 Rettig MB, Vescio RA, Pold M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J, Said JW, Berenson JR. (1997). Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from mutiple myeloma patients. *Science*, Vol 276 pp 18
- 5 26 Fischer T, Miller M, Bott-Silverman C, & Lichtin A. (1996). Posttransplant lymphoproliferative disease after cardiac transplantation. Two unusual variants with predominantly plasmacytoid features. *Transplantation*, Vol 62 (11) pp 1687-90.
- 5 27 Mackenzie J, Sheldon J, Morgan G, Cook G, Schulz TF, Jarrett RF. (1997). HHV-8 and multiple myeloma in the UK. *The Lancet* Vol 350 (9085) pp 1144-5.

- 5 28 Piras MA, Salis T, Naitana AV, Spanu L, Aceti A. (1996). HIV infection and neoplasia. *The Lancet* Vol 348 pp1316-7.
- 5 29 Schulz TF, Boshoff CH, Weiss RA. (1996). HIV infection and neoplasia. *The Lancet*, Vol 348 pp587-591.
- 5 30 Mussini C, Ghini M, Mascia MT, Giovanardi P, Zanni G, Lattuada I, Moreali S, Longo G, Ferrari MG, Torelli G. (1995). Monoclonal gammopathies and hepatitis C virus infection. *Blood*, Vol 85 pp1144-5.
- 5 31 Santini GF, Crovatto M, Modolo ML, Martelli P, Silvia C, Mazzi G, Franzin F, Moretti M, Tulissi P, Pozzato G. (1995). Waldenstrom macroglobulinemia: a role of HCV infection? Comment on *Blood* Vol 82 (9) p2932.
- 5 32 Silvestri F, Barillari G, Fanin R, Zaja F, Infanti L, Patriarca F, Baccarani M, Pipan C, Falasca E, Botta GA. (1996). Risk of hepatitis C virus infection, Waldenstrom's macroglobulinemia, and monoclonal gammopathies. *Blood*, Vol 88(3) pp1125-6.
- 5 33 Herrinton LJ. (1996). The epidemiology of monoclonal gammopathy of unknown significance: a review. *Current Topics in Microbiology & Immunology*, Vol 210, pp389-95.
- 5 34 Kyle RA. (1996). Monoclonal gammopathy of undetermined significance. *Current Topics in Microbiology & Immunology*, Vol 210, pp375-83.
- 5 35 Kristensen P, Andersen A, Irgens LM, Laake P, Bye AS. (1996). Incidence and risk factors of cancer among men and women in Norwegian agriculture. *Scand J Work Environ Health*, Vol 22 pp 14-26.
- 5 36 Rapiti E, Turi E, Forastiere F, Borgla P, Comba P, Perucci CA, & Axelson O. (1992). A mortality cohort study of seamen in Italy. *American Journal of Industrial Medicine*, Vol 21 pp 863-872.
- 5 37 Ireland B, Collins JJ, Buckley CF and Riordan SG. (1997) Cancer mortality among workers with benzene exposure. *Epidemiology*. 8(3):pp318-20, 1997 May.

- 5 38 Aksoy M, Erdem S, Dincol G, Kutlar A, Bakioglu I and Hepyukel T (1984) Clinical observations showing the role of some factors in the etiology of multiple myeloma. A study in 7 patients. *Acta Haematol* 71(2):pp116-120.
- 5 39 Kagan E & Jacobson RJ. (1983). Lymphoid and plasma cell malignancies: asbestos-related disorders of long latency. *AJCP*, Vol 80 (1) pp 14-20
- 5 40 Delzell E, & Grufferman S. (1985). Mortality among white and nonwhite farmers in North Carolina, 1976-1978. *American Journal of Epidemiology*, Vol 121 (3) pp 391-402.
- 5 41 Dean G. (1994). Deaths from primary brain cancers, lymphatic and haematopoietic cancers in agricultural workers in the Republic of Ireland. *Journal of Epidemiol. Community Health*, Vol. 48, pp. 364-368.
- 5 42 Divine BJ, & Hartmen CM. (1996). Mortality update of butadiene production workers. *Toxicology*, Vol. 113, pp. 169-181.
- 5 43 Khuder SA, & Mutgi AB. (1997). Meta-analyses of multiple myeloma and farming. *American Journal of Industrial Medicine*, Vol. 32, pp. 510-516.
- 5 44 Golden AL, Markowitz SB, Landrigan PJ. (1995). The risk of cancer in firefighters. *Occupational Medicine*, Vol 10 (4) pp 803-820.
- 5 45 Savitz DA, & Andrews KW. (1997). Review of epidemiologic evidence on benzene and lymphatic and hematopoietic cancers. *American Journal of Industrial Medicine*, Vol 31 (3) pp 287-95.
- 5 46 Paxton MB. (1996). Leukemia risk associated with benzene exposure in the pliofilm cohort. *Environmental Health Perspectives*, Vol 104 Suppl 6 pp 1431-6.
- 5 47 Fu H, Demers PA, Constantini AS, Winter P, Colin D, Kogevinas M, Boffetta P. (1996). Cancer mortality among shoe manufacturing workers: an analysis of two cohorts. *Occupational & Environmental Medicine*, Vol 53 (6) pp394-8.

- 5 48 Massoudi BL, Talbott EO, Day RD, Swerdlow SH, Marsh GM, & Kuller LH. (1997). A case-control study of hemotopoietic and lymphoid neoplasms: the role of work in the chemical industry. *American Journal of Industrial Medicine*, Vol 31 (1) pp 21-7.
- 5 49 Matanoski G, Elliot E, Tao X, Francis M, Correa-Villasenor A, & Santos-Burgoa C. (1997). Lymphomatopoietic cancers and butadiene and styrene exposure in synthetic rubber manufacture. *Annals of the NY Academy of Sciences*, Vol 837 pp 157-69.
- 5 50 Decoufle P, Blattner WA, & Blair A. (1983). Mortality among chemical workers exposed to benzene and other agents. *Environmental Research*, Vol 30 (1) pp 16-25.
- 5 51 Collingwood KW, Raabe GK, Wong O. (1996). An updated cohort mortality study of workers at a northeastern United States petroleum refinery. *International Archives of Occupational & Environmental Health*, Vol 68 (5) pp 277-88.
- 5 52 Golden AL, Markowitz SB, Landrigan PJ. (1995). The risk of cancer in firefighters. *Occupational Medicine: State of the Art Reviews*, Vol 10 (4) pp 803-820.
- 6 1 Tollerud DJ, Brinton LA, Stone BJ, Tobacman JK, & Blattner WA. (1985). Mortality from multiple myeloma among North Carolina furniture workers. *Journal of the National Cancer Institute*, Vol 74 (4) pp 799-801.
- 6 2 Milham S. (1971). Leukemia and multiple myeloma in farmers. *American Journal of Epidemiology*, Vol 94, pp. 307-310.
- 6 3 Lanes SF, Rothman KJ, Soden KJ, Amsel J & Dreyer NA. (1994). Mortality among synthetic fiber workers exposed to glycerol polyglycidyl ether. *American Journal of Industrial Medicine*, Vol 25(5), pp. 689-696.
- 6 4 Lickiss JN, Baikie AG and Panton J (1977). Lymphoproliferative and myeloproliferative disease in Tasmania. *National Cancer Institute Monographs*, Vol 47 pp 37-39.
- 6 5 Spinelli JJ, Gallagher RP, Band PR and Threlfall WJ (1984). Multiple myeloma, leukemia, and cancer of the ovary in cosmetologists and hairdressers. *American Journal of Industrial Medicine*, 6(2) pp 97-102.

- 6 6 Ketchum NS, Michalek JE, & Burton JE. (1999). Serum dioxin and cancer in veterans of operation ranch hand. *American Journal of Epidemiology*, Vol 149(7) pp 630-9.
- 6 7 Kayajanian GM (1999). Commentary: a critical review. Dioxin is a systemic promoter blocker, II. *Ecotoxicology and Environmental Safety*, Vol 42 pp 103-109.
- 6 8 Figgs LW, Dosemeci M and Blair A (1994). Risk of multiple myeloma by occupation and industry among men and women: a 24-State death certificate study. *Journal of Occupational Medicine*, 36(11) pp 1210-1221.
- 6 9 Pearce NE, Smith AH, Howard AH, Sheppard RA, Giles HJ, & Teague CA. (1986). Case-control study of multiple myeloma and farming. *Br J Cancer*, Vol 54 pp 493-500.
- 6 10 Pearce NE, Smith AH & Fisher DO. (1985). Malignant lymphoma and multiple myeloma linked with agricultural occupations in a New Zealand cancer registry-based study. *American Journal of Epidemiology*, Vol 121(2), pp. 225-237.
- 6 11 Brownson RC & Reif JS. (1988). A cancer registry-based study of occupational risk for lymphoma, multiple myeloma and leukaemia. *International Journal of Epidemiology*, Vol 17(1), pp. 27-32.
- 6 12 Brownson RC, Reif JS, Chang JC & Davis JR. (1989). Cancer risks among Missouri farmers. *Cancer*, Vol 64, pp. 2381-2386.
- 6 13 Kogevinas M, Sala M, Boffetta P, Kazerouni N, Kromhout H & Hoar-Zahm S. (1997). Cancer risk in the rubber industry: a review of the recent epidemiological evidence. *Occup Environ Med*, Vol 55, pp. 1-12.
- 6 14 Gallagher RP, Spinelli JJ, Elwood JM & Skippen DH. (1983). Allergies and agricultural exposure as risk factors for multiple myeloma. *Br J Cancer*, Vol 48, pp. 853-857.
- 6 15 Nandakumar A, Armstrong BK & De Klerk NH (1986). Multiple myeloma in Western Australia: a case-control study in relation to occupation, fathers's occupation, socioeconomic status and country of birth. *Int. J Cancer*, Vol 37, pp. 223-226.

- 6 16 Steineck G & Wiklund K. (1986). Multiple myeloma in Swedish agricultural workers. *International Journal of Epidemiology*, Vol 15(3), pp. 321-325.
- 6 17 Herrinton L, Weiss NS, Koepsell TD, Daling JR, Taylor JW, Lyon JL, Swanson M & Greenberg RS. (1994). Exposure of hair-colouring products and the risk of multiple myeloma. *American Journal of Public Health*, Vol 84(7), pp. 1142-1144.
- 6 18 Demiroglu H. (1997). Early age at onset in multiple myeloma and aetiological considerations in Turkey. *Eur J Haematol*, Vol 58, pp. 291-292.
- 6 19 Burnett CA, Halperin WE, Lulich NR and Sestito JP (1994). Mortality Among Fire Fighters: A 27 State Survey. *American Journal of Industrial Medicine* 26 pp 831-3.
- 6 20 Golstein BD (1990). Is Exposure to Benzene a Cause of Human Multiple Myeloma? *Annals of the New York Academy of Sciences* 609 pp 225-30.
- 6 21 Medline Search 1966 to July 1999 Week 3 of 8 pages
- 6 22 Medline Search 1966 to July 1999 Week 4 of 81 pages
- 6 23 Medline Search 1966 to July 1999 Week 3 of 92 pages
- 6 24 Medline Search 1966 to July 1999 Week 3 of 37 pages
- 6 25 Medline Search 1996 to August 1999 Week 2 of 53 pages
- 6 26 Medline Search 1996 to July 1999 Week 1 of 8 pages
- 6 27 Medline Search 1966 to March 1999 Week 5 of 46 pages
- 6 28 Medline Search 1996 to March 1999 Week 5 of 49 pages
- 6 29 Cuzick J & De Stavola B. (1988). Multiple myeloma- a case-control study. *British Journal of Cancer*, Vol 57 pp 516-520.
- 6 30 Zulian GB, Babare R, Zagonel V. (1998). Multiple myeloma. *Critical Reviews in Oncology-Hematology*, Vol 27(2) pp 165-7.

- 6 31 Sulzner SE, Amdur RJ, & Weider DJ. (1998). Extramedullary plasmacytoma of the head and neck. *American Journal of Otolaryngology*, Vol 19(3) pp 203-8.
- 6 32 Baba H, Maezawa Y, Furusawa N, Wada M, Kokubo Y, Imura S, Imamura Y, & Yamada Y. (1998). Solitary plasmacytoma of the spine associated with neurological complications. *Spinal Cord*, Vol 36(7) pp470-5.
- 7 1 Dalgleish A (1999)[ABSTRACT ONLY]. The relevance of non-linear mathematics (chaos theory) to the treatment of cancer, the role of the immune response and the potential for vaccines. *QJM*, 92(6) pp 347-359.
- 7 2 Divine BJ, Hartman CM and Wendt JK (1999)[ABSTRACT ONLY]. Update of the Texaco mortality study 1947-93: part II. Analyses of specific causes of death for white men employed in refining, research, and petrochemicals. *Occupational & Environmental Medicine*. 56(3), pp 174-180.
- 7 3 Bertoni-Salateo R, de Camargo B, Soares F, Chojniak R and Penna V (1998)[ABSTRACT ONLY]. Solitary plasmacytoma of bone in an adolescent. *Journal of Pediatric Hematology/Oncology*, 20(6) pp 574-576.
- 7 4 Goldberg S, Noel P, Klumpp T and Dewald G (1998)[ABSTRACT ONLY]. The erythroid leukemias: a comparative study of erythroleukemia (FAB M6) and Di Guglielmo Disease. *American Journal of Clinical Oncology*, 21(1) pp 42-47.
- 7 5 Huebner WW, Schnatter AR, Nicolich MJ and Jorgensen G (1997)[ABSTRACT ONLY]. Mortality experience of a young petrochemical industry cohort: 1979-1992 follow-up study of US-based employees. *Journal of Occupational & Environmental Medicine*, 39(10) pp 970-982.
- 7 6 Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T and Alexanian R (1997)[ABSTRACT ONLY]. Prognostic features of asymptomatic multiple myeloma. *British Journal of Haematology*, 97(4-II) pp 810-814.

- 7 7 Gordon PH, Rowland LP, Younger DS, Sherman WH, Hays AP, Louis ED, Lange DJ, Trojaborg W, Lovelace RE, Murphy PL and Latov N (1997)[ABSTRACT ONLY]. Lymphoproliferative disorders and motor neuron disease: an update. *Neurology*, 48(6) pp 1671-1678.
- 7 8 Hess M (1951). *Paint Film Deffects: Their causes and cure*. Chapman & Hall, London, Appendix (Section 65) pp 173-193.
- 7 9 Chen BP, Galy AM, Fraser C and Hill B (1997)[ABSTRACT ONLY]. Delineation of the human hematolymphoid system: potential applications of defined cell populations in cellular therapy. *Immunological Reviews*, Vol 157 pp 41-51.
- 7 10 Martyn CN and Hughes RAC (1997)[ABSTRACT ONLY]. Epidemiology of peripheral neuropathy. *Journal of Neurology, Neurosurgery & Psychiatry*, 62(4) pp 310-318.
- 7 11 Pich A, Chiusa L, Marmont F and Navone R (1997)[ABSTRACT ONLY]. Risk groups of Myeloma patients by histologic pattern and proliferative activity. *American Journal of Surgical Pathology*, 21(3) pp 339-347.
- 7 12 Winther JF, Ulbak K, Dreyer LI, Pukkala E and Osterlind A (1997)[ABSTRACT ONLY]. Radiation. *APMIS, Supplementum*, Vol 105 Supplementum No. 76 pp 83-99.
- 7 13 Clavel J, Conso F, Limasset JC, Mandereau L, Roche P, Flandrin G and Hemon D (1996)[ABSTRACT ONLY]. Hairy cell leukaemia and occupational exposure to benzene. *Occupational & Environmental Medicine*, 53(8) pp 533-539.
- 7 14 Kosmas C, Viniou NA, Stamatopoulos K, Courtenay-Luck NS, Papadaki T, Kollia P, Paterakis G, Anagnostou D, Yataganas X and Loukopoulos D (1996)[ABSTRACT ONLY]. Analysis of the kappa light chain variable region in multiple myeloma. *British Journal of Haematology*, 94(2), pp306-317.
- 7 15 National Cancer Institute (1999). Plasma cell neoplasm: General information.
[http://cancernet.nci.nih.gov/clinpdq/soa/Pasma_cel_neoplasm_Physician.htm]
- 7 16 Medline Search 31/08/1999 of 104 pages

- 7 17 Athanasou NA. (1996). Cellular biology of bone-reabsorbing cells. *The Journal of Bone & Joint Surgery*, Vol 78-A(7) pp 1096-1113.
- 7 18 Laso FJ, Taberero MD, Iglesias-Osma MC. (1998). Extramedullary plasmacytoma: a localized or systemic disease? *Annals of Internal Medicine*, Vol 128(2) p 156.
- 7 19 Goedert JJ, Cote TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, Jaffe ES, Biggar RJ. (1998). Spectrum of AIDS-associated malignant disorders. *The Lancet*, Vol 351 (9119) pp 1833-9.
- 7 20 Pasqualetti P, Collacciani A, & Casale R. (1996). Risk of monoclonal gammopathy of undetermined significance: a case-referent study. *American Journal of Hematology*, Vol 52 (3) pp 217-220.
- 7 21 Cantor KP & Blair A. (1984). Farming and mortality from multiple myeloma: a case-control study with the use of death certificates. *Journal of the National Cancer Institute*, Vol 72(2) pp 251-5.
- 7 22 Pukkala E. (1995). Cancer risk by social class and occupation. A survey of 109,000 cancer cases among Finns of working age. Vol 7 *Contributions to Epidemiology and Biostatistics*.
- 8 1 Howe GR & Lindsay JP. (1983). A follow-up study of a ten-percent sample of the Canadian Labor Force. 1. Cancer Mortality in males, 1965-73.
- 8 2 Giles GG, Lickiss JN, Baikie MJ, Lowenthal RM, & Panton J. (1984). Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: occupational and familial aspects. *JNCI* Vol 72 (6) pp 1233-1240.
- 8 3 Longo DL (1998). Plasma cell disorders. *Harrison's Principles of Internal Medicine 14th Edition*. Fauci AS, Braunwald E, Isselbacher KJ, et al (Eds). McGraw-Hill New York Chapter 144 pp 712-3.
- 8 4 White RF, Proctor SP. (1997). Solvents and neurotoxicity. *The Lancet*, Vol 349 pp 1239-43.

- 8 5 McLaughlin JK, Linet MS, Stone BJ, Fraumeni Jr JF, Malker HSR, Weiner JA, Ericsson JLE. (1988). Multiple myeloma and occupation in Sweden. *Archives of Environmental Health*, Vol 43(1) pp7-10.
- 8 6 Satin KP, Wong O, Yuan LA, Bailey WJ, Newton KL, Wen C-P, Swencicki RE. (1996). A 50-year mortality follow-up of a large cohort of oil refinery workers in Texas. *Journal of Occupational Environmental Medicine*, Vol 38 pp 492-506.
- 8 7 Englund A. (1980). Cancer incidence among painters and some allied trades. *Journal of Toxicology Environmental Health*, Vol 6 pp 1267-1273.
- 8 8 Anttila A, Pukkala E, Riala R, Sallmen M, Hemminki K. (1998). Cancer incidence among Finnish workers exposed to aromatic hydrocarbons. *Int Arch Occup Environ Health*, Vol 71 pp 187-193.
- 8 9 Yin S-N, Hayes RB, Linet MS, Li G-L, Dosemeci M, Travis LB, Li C-Y, Zhang Z-N, Li D-G, Chow W-H, Wacholder S, Wang Y-Z, Jiang Z-L, Dai T-R, Zhang W-y, Chao X-J, Ye P-Z, Kou Q-R, Zhang X-C, Lin X-F, Meng J-F, Ding C-Y, Zho J-S, & Blot WJ. (1996). A cohort study of cancer among benzene-exposed workers in China: Overall results. *American J of Indust Med*, Vol 29, pp227-235.
- 8 10 Jarvholm B, Mellblom B, Norrman R, Nilsson R, Nordlinder R. (1997). Cancer incidence of workers in the Swedish petroleum industry. *Occupational and Environmental Medicine*, Vol 54 pp 686-691.
- 8 11 Mastrangelo G, Fadda E, & Marzia V. (1996). Polycyclic aromatic hydrocarbons and cancer in man. *Environmental Health Perspectives*, Vol 104 (11) pp 1166-1170.
- 8 12 Gallagher RP, Threlfall WJ. (1983). Cancer mortality in metal workers. *Canadian Medical Association Journal*, Vol 129 pp 1191-4.
- 8 13 Greene MH, Hoover RN, Eck RL, & Fraumeni JF, jr. (1979). Cancer mortality among printing plant workers. *Environmental Research*, Vol 20 pp 66-73.

- 8 14 Mikkelsen S. (1980). A cohort study of disability pension and death among painters with special regard to disabling presenile dementia as an occupational disease. *Scand J Soc Med Suppl* 16 pp 34-43.
- 8 15 Olsen JH, Jensen OM. (1987). Occupation and risk of cancer in Denmark. An analysis of 93 810 cancer cases, 1970-1979. *Scand J Work Environ Health*, Vol 13 Suppl1 pp 1-91.
- 8 16 Matanoski GM, Stockwell HG, Diamond EL, Haring-Sweeney M, Joffe RD, Mele LM, Johnson ML. (1986) A cohort mortality study of painters and allied tradesmen. *Scand J Work Environ Health*, Vol 12 pp 16-21.
- 8 17 Engholm G, Englund A, Lowing H. (1987). Cancer incidence and mortality among Swedish painters. *Scand J of Work Environ & Health*, Vol 13 p181.
- 8 18 Whorton MD, Schulman J, Larson SR, Stubbs HA, & Austin D. (1983). Feasibility of identifying high-risk occupations through tumor registries. *Journal of Occupational Medicine*, Vol 25 (9) pp 657-660.
- 8 19 Viadana E, Bross DJ, & Houten L. (1976). Cancer experience of men exposed to inhalation of chemicals or to combustion products. *Journal of Occupational Medicine*, Vol 18 (12) pp 787-792.
- 8 20 Morgan RW, Kaplan SD, & Gaffey WR. (1981). A general mortality study of production workers in the paint and coatings manufacturing industry. A preliminary report. *Journal of Occupational Medicine*, Vol 23 (1) pp 13-21.
- 8 21 Chiazze L, Ference LD, & Wolf PH. (1980). Mortality among automobile assembly workers. *Journal of Occupational Medicine*, Vol 22(8) pp520-6.
- 8 22 Dalager NA, Mason TJ, Fraumeni JF, Hoover R, & Payne WW. (1980). Cancer mortality among workers exposed to zinc chromate paints. *Journal of Occupational Medicine*, Vol 22(1) pp 25-9.

- 8 23 Raabe GK, Collingwood KW, & Wong O. (1998). An updated mortality study of workers at a petroleum refinery in Beaumont, Texas. *American Journal of Industrial Medicine*, Vol 33(1) pp 61-81.
- 8 24 Dement JM, Hensley L, Kieding S, & Lipscomb H. (1998). Proportionate mortality among union members employed at three Texas refineries. *American Journal of Industrial Medicine*, Vol 33(4) pp 327-4.
- 8 25 NIOSH. Publication No. 77-178. A retrospective survey of cancer in relation to occupation.
- 9 1 Kaplan SD (1986). Update of a mortality study of workers in petroleum refineries. *Journal of Occupational Medicine*, 28(7) pp 514-516.
- 9 2 Ott MG, Carlo GL, Steinberg S and Bond GG (1985). Mortality among employees engaged in chemical manufacturing and related activities. *American Journal of Epidemiology*, 122(2) pp 311-322.
- 9 3 Boffetta P, Jourenkova N and Gustavsson P (1997). Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. *Cancer Causes and Control*, Vol 8 pp 444-472.
- 9 4 Tolbert PE (1997). Oils and cancer. *Cancer Causes and Control*, Vol 8 pp 386-405.
- 9 5 Ward EM, Burnett CA, Ruder A and Davis-King K (1997). Industries and cancer. *Cancer Causes and Control*, Vol 8 pp 356-370.
- 9 6 Lundberg I, Milatou-Smith R. (1998). Mortality and cancer incidence among Swedish paint industry workers with long-term exposure to organic solvents. *Scand J Environ Health*, Vol 24 (4) pp 270-5.
- 9 7 Blair A, Hartge P, Stewart PA, McAdams M & Lubin J. (1998). Mortality and cancer incidence of aircraft maintenance workers exposed to trichloroethylene and other organic solvents and chemicals: extended follow up. *Occupational & Environmental Medicine*, Vol 55, pp161-171.

- 9 8 Watanabe KK, Kang HK, & Thomas TL. (1991). Mortality among Vietnam veterans: with methodological considerations. *Journal of Occupational Medicine*, Vol 33 (7) pp 780-5.
- 9 9 Guberan E, Usel M, Raymond L, Tissot R, Sweetnam PM. (1989). Disability, mortality, and incidence of cancer among Geneva painters and electricians: a historical prospective study. *British Journal of Industrial Medicine*, Vol 46 pp 16-23.
- 9 10 Vineis P, D'Amore F, & Working group on the epidemiology of hematology lymphopoietic malignancies in Italy. (1992). The role of occupational exposure and immunodeficiency in B-Cell malignancies. *Epidemiology*, Vol 3 (3) pp 266-70.
- 9 11 Lindsay JP, Stavrakys KM, Howe GR. (1993). The Canadian labour force ten percent sample study. Cancer mortality among men, 1965-1979. *Journal of Occupational Medicine*, Vol 35 (4) pp 408-414.
- 9 12 Hotz P & Lauwerys RR. (1997). Hematopoietic and lymphatic malignancies in vehicle mechanics. *Critical Reviews in Toxicology*, Vol 27 (5) PP 443-494
- 9 13 Lynge E, Anttila A, & Hemminki K. (1997). Organic solvents and cancer. *Cancer Causes & Control*, Vol 8 (3) pp 406-19.
- 9 14 Lynge E, Andersen A, Nilsson R, Barlow L, Pukkala E, Nordlinder R, Boffetta P, Grandjean P, Heikkila P, Horte L-G, Jakobsson, Lundberg I, Moen B, Partanen T & Riise T. (1997). Risk of cancer and exposure to gasoline vapors. *American Journal of Epidemiology*, Vol 145, 5, pp449-458.
- 9 15 Doody MM, Linet MS, Glass AG, Curtis RE et al (1996). Risks of non Hodgkin's lymphoma, multiple myeloma, and leukemia associated with common medications. *Epidemiology* 7 (2) pp 131-139
- 9 16 Schnatter AR, Armstrong TW, Nicolich MJ, Thompson FS, Katz AM, Huebner WW, Pearlman ED (1996) Lymphohaematopoietic malignancies and quantitative estimates of exposure to benzene in Canadian petroleum distribution workers. *Occupational Environmental Med*; Vol 53, pp773-781

- 9 17 Chen R & Seaton A (1996). A meta-analysis of mortality among workers exposed to organic solvents. *Occupational Medicine*, Vol 46, pp 337-344.
- 9 18 Firth HM; Cooke KR & Herbison GP (1996). Male cancer incidence by occupation: New Zealand, 1972-1984. *International Journal of Epidemiology*, Volume 25(1), pp 14-21.
- 9 19 Wong O. (1987). An industry wide mortality study of chemical workers occupationally exposed to benzene. I general results. *British Journal of Industrial Medicine*, Vol. 44, pp. 365-381.
- 9 20 Spirtas R, Stewart PA, Lee JS, et al. (1991). Retrospective cohort mortality study of workers at an aircraft maintenance facility. I epidemiological results. *British Journal of Industrial Medicine*, Vol. 48, pp. 515-530.
- 9 21 International Agency for Research on Cancer. (1987). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Overall Evaluations of Carcinogenicity: An updating of IARC Monographs Volumes 1 to 42, Supplement 7. World Health Organization.
- 9 22 Watanabe KK and Kang HK (1996). Mortality patterns among Vietnam Veterans: a 24-year retrospective analysis. *JOEM*, 38(3) pp 272-278.
- 9 23 Lundberg, I. (1986). Mortality and cancer incidence among Swedish paint industry workers with long-term exposure to organic solvents. *Scandinavian Journal of Work, Environment and Health*, Vol. 12, pp. 108-113.
- 9 24 Marsh GM, Enterline PE and McCraw D (1991). Mortality Patterns Among Petroleum Refinery and Chemical Plant Workers'. *Am J Ind Med* 19; 1991; pp.29-42.
- 9 25 Alderson M (1986). *Occupational Cancer*. Publication of the office of Population Censuses and Surveys, London: Butterworths. Benzene - Ch 2.8 pp 43-46.
- 9 26 Thomas TL, Waxweiler RJ, Crandall MS, White DW, Moure-Eraso R and Fraumeni, Jr, JF (1984). Cancer mortality patterns by work category in three Texas oil refineries. *Am. Journal of Industrial Medicine* Vol 6 pp 3-16.

- 9 27 Breslin P, Kang HK, Lee Y, Burt V and Shepard BM (1988). Proportionate mortality study of US army and US marine corps veterans of the Vietnam war. *Journal of Occupational Medicine* 30(5) pp 412-419.
- 9 28 Namboodiri KK and Harris RE (1991). Hematopoietic and lymphoproliferative cancer among male veterans using the Veterans Administration Medical System. *Cancer* Vol 68 pp 1123-1130.
- 9 29 Gridley G, McLaughlin JK, Ekblom A, et al (1993) Incidence of Cancer Among Patients with Rheumatoid Arthritis *Journal of the National Cancer Institute* 85(4) 17 February 1993 pp 307 - 311.
- 10 1 Institute of Medicine. *Veterans and Agent Orange: Update 1998*. National Academy Press, Washington DC 1999
- 10 2 IARC (1989) *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Organic Solvents, Resin Monomers and Related Compounds, Pigments and Occupational Exposures in Paint Manufacture and Painting*. WHO. IARC, Lyon, France. Vol 47
- 10 3 Schrier SL (1997). Multiple myeloma and related serum protein disorders. *Scientific American Medicine*, Dale DC & Federman DD (eds). Scientific American Inc. New York Chapter 5, Section 1X p 1-5.
- 10 4 Crane PJ, Bernard DI, Horsley KD, Adena MA (1997). *Mortality of Vietnam Veterans: The veteran cohort study. A report of the 1996 retrospective cohort study of Australian Vietnam veterans*. Canberra: Department of Veterans' Affairs, 1997. ISBN 0 642 270